Nirsevimab Effective Against RSV-Linked Bronchiolitis Hospitalization

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, July 10, 2024 -- Nirsevimab therapy is effective for reducing the risk for hospitalization for respiratory syncytial virus (RSV)-associated bronchiolitis among infants, according to a study published in the July 11 issue of the New England Journal of Medicine.

Zein Assad, M.D., from the Robert Debré University Hospital in Paris, and colleagues conducted a prospective, multicenter, matched case-control study to analyze the effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis in infants. Case patients were infants younger than 12 months of age who were hospitalized for RSV-associated bronchiolitis. Control patients were infants with clinical visits for conditions unrelated to RSV infection. The study included 1,035 infants: 690 case patients and 345 controls matched on the basis of age, date of hospital visit, and study center.

Overall, 60 and 97 case and control patients, respectively, had received nirsevimab previously. The researchers found that the estimated adjusted effectiveness of nirsevimab therapy was 83.0 percent against hospitalization for RSV-associated bronchiolitis. Similar results were seen in a sensitivity analysis as those in the primary analysis. The effectiveness of nirsevimab therapy was 69.6 and 67.2 percent against RSV-associated bronchiolitis resulting in critical care and against RSV-associated bronchiolitis resulting in ventilatory support, respectively.

"Nirsevimab prophylaxis was effective against RSV-associated bronchiolitis leading to hospitalization among infants younger than 12 months of age, including those with severe cases that led to pediatric intensive care unit admission and ventilatory support," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-11 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords